Triomics Secures $22M to Bring Oncology-Specific AI to Cancer Centers | TechCrunch

triomics-secures-$22m-to-bring-oncology-specific-ai-to-cancer-centers-|-techcrunch

Triomics Secures $22M to Bring Oncology-Specific AI to Cancer Centers | TechCrunch

Triomica startup building an AI-powered platform to help oncologists and administrative staff automate data-intensive tasks such as clinical trial matching and appointment preparation, has raised $22 million in Series B funding.

The round was led by Battery Ventures, with participation from returning backers Nexus Venture Partners, Lightspeed, Y Combinator and others.

The good news is that advances in oncology are allowing patients to stay alive longer. This welcome trend, however, involves creating dense, multi-year medical records that take a lot of time for healthcare workers to review and decipher.

A typical medical record includes doctor progress notes, imaging and pathology reports, and even fax scans. “We have seen the medical records [with] thousands of pages of information,” Sarim Khan, co-founder of Triomics, told TechCrunch.

Founded in 2021, the startup raised a $15 million in Series A in mid-2024. Initially focused on helping physicians identify the most suitable clinical trials for their patients, Triomics expanded its platform as LLM capabilities expanded. Over the past two years, Triomics has added auditable patient summaries to its platform, surfacing key information directly in the tools clinicians already use, without them needing to switch applications.

By reducing appointment preparation time, these summaries give oncologists more time with their patients. The efficiency gain matters beyond individual appointments: In oncology, where patient histories are unusually complex and staff burnout is a persistent problem, tools that reduce administrative burden have an outsized impact.

Triomics is also used to automate the tedious task of submitting tumor reports to government registries, a legal mandate for cancer centers.

While generic AI agents excel at basic summaries, leading institutions like Memorial Sloan Kettering (MSK) and the Yale Cancer Center use Triomics because its models are trained specifically on oncology data, Khan explained.

Triomics’ most direct competition comes from AI medical scribes like Abridge and Microsoft’s Nuance – tools that use AI to listen to and document patient-doctor conversations – when it comes to summarizing patient records.

Despite fierce competition, Triomics is growing rapidly. According to Khan, the startup quadrupled its enterprise customer base over the past year, leading to a 10-fold increase in its annualized recurring revenue.

Pictured left to right: Sarim Khan, co-founder and CEO of TriomicsAnd Hritura Singhco-founder and CTO of Triomics.

When you purchase through links in our articles, we may earn a small commission. This does not affect our editorial independence.

Marina Temkin is a venture capital and startups reporter at TechCrunch. Before joining TechCrunch, she wrote about venture capital for PitchBook and Venture Capital Journal. Earlier in her career, Marina was a financial analyst and earned her CFA designation.

You can contact or check Marina’s outreach by sending an email marina.temkin@techcrunch.com or via encrypted message at +1 347-683-3909 on Signal.

View biography

Exit mobile version